A small but key UK study has found that "cellular immunity" to the pandemic SARS-CoV-2 virus is present after six months in people who had mild or asymptomatic COVID-19 - suggesting they might have ...
Breakthrough method turns ‘cold’ tumors into immune targets, raising hope for lasting cancer control - Anadolu Ajansı ...
The FDA has approved Kedrion Biopharma’s Qivigy, a 10% IV immunoglobulin therapy, for treating adults who have primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback